Beyond Air, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Corporate Update

On February 10, 2025, Beyond Air, Inc. (NASDAQ: XAIR) released its financial results for the fiscal third quarter ended December 31, 2024. The company reported a 34% increase in revenues compared to the previous quarter, exceeding $1 million. Beyond Air also received CE Mark for its LungFit PH device in Europe and obtained Market Authorization in Australia, with international shipments set to commence later in the year.

The company is a commercial stage medical device and biopharmaceutical firm focused on utilizing nitric oxide (NO) to enhance patient outcomes. Steve Lisi, Chairman and CEO of Beyond Air, expressed optimism about the progress made in commercial efforts, particularly with the expansion of hospitals using LungFit PH in the U.S. Lisi highlighted the company’s success in the global market following the CE Mark certification in Europe and the market authorization in Australia.

The financial statement for the fiscal quarter ended December 31, 2024, revealed revenues of $1.1 million compared to $0.4 million for the same period in 2023 and $0.8 million for the previous quarter ended September 30, 2024. Additionally, the company reported cost of revenue, research and development expenses, selling, general, and administrative expenses, as well as other financial details in the filing.

In terms of upcoming milestones, Beyond Air outlined its commercial execution plans for LungFit PH, including increasing demand and securing regulatory approvals in various countries. The company’s pipeline highlights include the CE Mark certification for LungFit PH, enabling market penetration in the European Union and other designated regions.

The financial report for the quarter detailed a loss from operations, operating expenses, as well as other income and expenses. Beyond Air reported cash, cash equivalents, and marketable securities of $10.9 million as of December 31, 2024, with total debt outstanding at $11.8 million. The company anticipates adequate cash runway to support its operations through 2026.

Furthermore, Beyond Air is actively engaged in clinical trials for its LungFit systems, targeting severe lung infections and solid tumors. The company continues to advance its medical devices and remains committed to utilizing nitric oxide for improving patient outcomes across various medical conditions.

Investors can access the conference call and webcast for more details on the company’s financial performance and future prospects.

Please note that the information provided here is a summary of the 8-K SEC filing for Beyond Air, Inc. Investors and stakeholders are encouraged to refer to the full filing for comprehensive details and disclosures.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Beyond Air’s 8K filing here.

About Beyond Air

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.